Nifty Healthcare Index News and Updates

Name: Latest research reports of Lupin Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 5
Author: Geojit BNP Paribas

Keep track of all breaking news on Nifty Healthcare Index from all sources in a single place.

Load latest

Dr. Reddy's Laboratories Ltd.

25 Nov 2025

1270.00

0.79%

Dr. Reddy's Laboratories shares jump over 1% as European Commission approves biosimilar AVT03

Economic Times

Dr. Reddy's Laboratories secured European Commission approval for AVT03, a biosimilar to Prolia and Xgeva, for osteoporosis and bone complications. This significant milestone, following a positive CHMP recommendation, allows marketing across EU member states and EEA countries. Dr. Reddy's, in partnership with Alvotech, will commercialize the drug under brands Acyvbra and Xbonzy.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr Reddy's gets marketing authorisation for biosimilar fromEuropean Commission

Business Line | 24 Nov 2025

Lupin Ltd.

25 Nov 2025

2082.10

0.01%

LUPIN LIMITED

Buy: Lupin Ltd.

Recommendation Target

Geojit BNP Paribas

In Q2FY26, Lupin reported a consolidated revenue of Rs. 7,048cr, up 24.2% YoY, Lupin's India segment revenue rose 3.4% YoY to Rs. 2,078cr, led by an 8.8% growth in Rx business, strong chronic therapy momentum and robust volume growth,...

Geojit BNP Paribas upgraded Lupin Ltd. to Buy with a price target of 2225.0 on 25 Nov, 2025.

Dr. Reddy's Laboratories Ltd.

24 Nov 2025

1270.00

0.79%

Policymakers-industry partnership vital for healthcare delivery: Dr Reddy's

Business Standard

Dr Reddy's Laboratories on Monday said partnerships between policymakers and industry are vital to build a future-ready healthcare system that serves millions. Satish Reddy, the chairman of the Hyderabad-based drug major, joined industry leaders at the sixth Pre-Budget Consultation chaired by Union Finance Minister Nirmala Sitharaman in the national capital. He shared his perspective on the importance of risk-based innovation funding to strengthen India's pharmaceutical ecosystem and accelerate breakthroughs that improve patient access and affordability. "At Dr Reddy's, we believe that partnerships between policymakers and industry are vital to building a future-ready healthcare system that serves millions," Reddy said in a post shared by the drug firm on social networking platform LinkedIn.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Apollo Hospitals Enterprise Ltd.

24 Nov 2025

7239.00

-0.67%

Apollo Hospitals opens new 400-bed quaternary care facility in Pune

Business Standard

Apollo Hospitals has inaugurated its newest quaternary care centre in Pune, expanding its western India network with advanced specialties, digital systems, and high-acuity services

Apollo Hospitals Enterprise Ltd. is trading above its 200 day SMA of 7188.0

Apollo Hospitals rolls out its third facility in Maharashtra with a 400-bed quaternary care facility in Pune

Business Line | 24 Nov 2025 1 more

Dr. Reddy's Laboratories Ltd.

24 Nov 2025

1270.00

0.79%

Dr Reddy's Gets European Nod For Biosimilar To Treat Osteoporosis

NDTV Profit

Prolia is a prescription medicine used to treat osteoporosis in women who have been through menopause and in men who are at increased risk of fractures.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Max Healthcare Institute Ltd.

24 Nov 2025

1115.10

-0.92%

Today's Stock Recommendation: November 24, 2025

Business Line

The stock idea that we have for you today is Max Healthcare Institute

Axis Direct decreased Buy price target of Max Healthcare Institute Ltd. to 1425.0 on 18 Nov, 2025.

Stock to buy today: Max Healthcare Institute (1,180.75) BUY

Business Line | 24 Nov 2025

Aurobindo Pharma Ltd.

23 Nov 2025

1209.80

-0.53%

Aurobindo Pharma incurring loss at China Plant; hopes to achieve break-even by Q4

Business Line

In the US, Dayton (facility) has transitioned into the commercial phase, with manufacturing underway, packaging approval secured, and product launches scheduled from January, positioning the site to start contributing significant revenues in FY27

Promoters pledged 0.42% of shares in last quarter. Total pledge stands at 17.50% of promoter holdings

Aurobindo Pharma Incurring Loss At China Plant, Aims Break-Even By Q4

NDTV Profit | 23 Nov 2025 1 more

Max Healthcare Institute Ltd.

21 Nov 2025

1115.10

-0.92%

Max Healthcare builds growth runway with brownfield expansion push

Business Standard

Max Healthcare's Q2 results show strong volume growth, rising international patient revenue and solid margins, with brownfield additions and added bed capacity supporting a multi-year expansion cycle

Max Healthcare Insti.. has an average target of 1348.00 from 5 brokers.

Lupin Ltd.

20 Nov 2025

2082.10

0.01%

Lupin, Fortis Among Axis Securities Top 'Buy' In Pharma, Healthcare Space; Q2 Review Details Inside

NDTV Profit

The healthcare space continues to outperform and pharma sector impacted by US generics in Q2, adds the brokerage.

Lupin Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

20 Nov 2025

6389.50

-0.51%

Healthy CS traction and favorable mix boosted profitability even as generics remained soft

Accumulate: Divi's Laboratories Ltd.

Target

Deven Choksey

Divi’s enters the second half of FY26 with a healthy execution pipeline across Custom Synthesis, supported by multiple projects progressing through validation and expected to commercialize over the next 1–2 years.

Deven Choksey increased Accumulate price target of Divi's Laboratories Ltd. to 6795.0 on 20 Nov, 2025.

Nifty Healthcare Index PB	5.6
Nifty Healthcare Index PE	37.2
Nifty Healthcare Index DIV	0.6
Nifty Healthcare Index EPS	399.9

Near 52W High of ₹15112.50

Nifty Healthcare Index PB

Nifty Healthcare Index PE

Nifty Healthcare Index DIV

Nifty Healthcare Index EPS

Nifty Healthcare Index News and Updates

Keep track of all breaking news on Nifty Healthcare Index from all sources in a single place.